Skip to content

Tumor Immune Microenvironment and VAF-inferred BRCA1/2 Loss of Heterozygosity in Japanese Patients With Germline BRCA1/2-mutated Breast Cancer

Oct 2026 · Anticancer Research · Vol 46, pp. 6099 - 6111 · 0 citations · 19 references
Medicine

Abstract

Background/Aim: Germline BRCA1/2 mutations (gBRCA1/2m) confer a markedly increased lifetime risk of breast cancer. Although diverse second-hit mechanisms lead to biallelic inactivation of BRCA1/2, their relationship with the immune microenvironment remains poorly understood, particularly in Japanese populations. Patients and Methods: We retrospectively analyzed 22 Japanese patients with gBRCA1/2m breast cancer who underwent curative surgery. Pathological evaluation included assessment of tumor-infiltrating lymphocytes (TILs), CD4+, CD8+, and FOXP3+ T-cell infiltration, and PD-L1 expression. Targeted next-generation sequencing of tumor samples identified somatic alterations. Loss of heterozygosity (LOH) at the BRCA1/2 locus was assessed using tumor-only sequencing data based on variant allele frequency (VAF). After adjustment for tumor cellularity, LOH was stringently defined as a modified VAF ≥0.90; cases not meeting this threshold were classified as non-LOH. Results: Twelve patients carried gBRCA1m and 10 carried gBRCA2m. High immune infiltration and frequent PD-L1 expression (68.2%) were observed, with a trend toward greater immune activity in BRCA1-mutated tumors. Of 14 cases with reportable sequencing results, LOH status was evaluable in 13. LOH was identified in 6 (46.2%) cases. LOH was more frequent in BRCA2-mutated tumors (75.0%) than in BRCA1-mutated tumors (33.3%). No differences were observed between LOH and non-LOH groups in CD4+, FOXP3+, or CD8+ T-cell infiltration, stromal TIL levels, PD-L1 expression, or disease-free survival. Conclusion: In this Japanese cohort of BRCA-mutated breast cancer, integrated genomic and pathological analyses revealed heterogeneity in second-hit mechanisms and immune microenvironment features and suggested that detectable LOH does not fully account for immune activation in these tumors.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.